SeaSpine Holdings Corporation (NASDAQ:SPNE) has received an average broker rating score of 1.00 (Strong Buy) from the three analysts that cover the company, Zacks Investment Research reports. Three equities research analysts have rated the stock with a strong buy recommendation.

Brokers have set a 12-month consensus price target of $18.00 for the company and are predicting that the company will post ($0.59) earnings per share for the current quarter, according to Zacks. Zacks has also assigned SeaSpine an industry rank of 170 out of 265 based on the ratings given to its competitors.

Several brokerages recently issued reports on SPNE. HC Wainwright restated a “buy” rating and set a $15.00 price objective on shares of SeaSpine in a research report on Friday, November 3rd. Piper Jaffray Companies restated a “buy” rating and set a $22.00 price objective on shares of SeaSpine in a research report on Sunday, August 20th. BTIG Research restated a “buy” rating on shares of SeaSpine in a research report on Monday, November 6th. Finally, Zacks Investment Research upgraded SeaSpine from a “hold” rating to a “buy” rating and set a $13.00 price objective for the company in a research report on Tuesday, September 12th.

Shares of SeaSpine (SPNE) traded down $0.23 during trading on Tuesday, hitting $10.16. The company had a trading volume of 44,064 shares, compared to its average volume of 58,114. SeaSpine has a 1 year low of $6.31 and a 1 year high of $13.46.

Institutional investors have recently modified their holdings of the stock. Hodges Capital Management Inc. raised its position in shares of SeaSpine by 50.0% during the 3rd quarter. Hodges Capital Management Inc. now owns 180,000 shares of the medical equipment provider’s stock worth $2,020,000 after purchasing an additional 60,000 shares during the last quarter. OxFORD Asset Management LLP acquired a new position in SeaSpine in the 2nd quarter valued at $288,000. Falcon Point Capital LLC raised its holdings in SeaSpine by 15.9% in the 2nd quarter. Falcon Point Capital LLC now owns 108,949 shares of the medical equipment provider’s stock valued at $1,255,000 after acquiring an additional 14,982 shares during the last quarter. Gilder Gagnon Howe & Co. LLC acquired a new position in SeaSpine in the 3rd quarter valued at $4,024,000. Finally, Schwab Charles Investment Management Inc. raised its holdings in SeaSpine by 1.0% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 18,707 shares of the medical equipment provider’s stock valued at $216,000 after acquiring an additional 190 shares during the last quarter. Hedge funds and other institutional investors own 43.43% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Brokerages Set $18.00 Target Price for SeaSpine Holdings Corporation (SPNE)” was reported by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another website, it was stolen and reposted in violation of U.S. & international copyright legislation. The legal version of this story can be viewed at https://www.americanbankingnews.com/2017/11/28/brokerages-set-18-00-target-price-for-seaspine-holdings-corporation-spne.html.

SeaSpine Company Profile

SeaSpine Holdings Corporation is a medical technology company. The Company is focused on the design, development and commercialization of surgical solutions for the treatment of patients suffering from spinal disorders. The Company operates through the development, manufacture and marketing of orthobiologics and spinal fusion hardware segment.

Get a free copy of the Zacks research report on SeaSpine (SPNE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for SeaSpine Holdings Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SeaSpine Holdings Corporation and related companies with MarketBeat.com's FREE daily email newsletter.